Department of Otolaryngology, School of Medicine, Showa University, Tokyo, Japan.
Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
Thymus- and activation-regulated chemokine (TARC) and macrophage-derived chemokine (MDC) are accepted to be important molecules in the development and maintenance of allergic diseases. Although several types of histamine H(1) receptor antagonist (antihistamine) have been developed and used for the treatment of allergic diseases, the influence of antihistamines on TARC and MDC production is not well understood.
The present study was undertaken to examine the influence of antihistamines on TARC and MDC production from CD14+ cells after antigenic stimulation in vitro.
CD14+ cells prepared from patients with pollinosis to Japanese cedar pollen were stimulated with specific allergen extracted from Japanese cedar pollen (Cry j 1) in the presence of azelastine (AZE), ketotifen (KET), fexofenadine (FEX) and oxatomide (OXA) for 6 days. TARC and MDC levels in culture supernatants were examined by ELISA. We also examined the influence of FEX on TARC and MDC mRNA expression, phosphorylation of mitogen-activated protein kinases (MAPKs) and transcription factor activation in CD14+ cells after Cry j 1 stimulation.
FEX at 250 ng/ml, which is almost equal to therapeutic blood levels, caused a significant inhibition of TARC and MDC production.However, AZE, OXA and KET required higher concentrations than their therapeutic blood levels to suppress production of these factors. FEX at 250 ng/ml also suppressed NF-κB activation, phosphorylation of p38 MAPK and extracellular signal-regulated kinases 1 and 2 and expression of mRNA for TARC and MDC.
These results suggest that antihistamines, especially FEX, suppress CC chemokine production from CD14+ cells through interference with antigen-mediated signaling and result in favorable modification of allergic disease states or conditions.
胸腺和活化调节趋化因子(TARC)和巨噬细胞衍生趋化因子(MDC)被认为是过敏性疾病发展和维持的重要分子。尽管已经开发并使用了几种类型的组胺 H(1)受体拮抗剂(抗组胺药)来治疗过敏性疾病,但抗组胺药对 TARC 和 MDC 产生的影响尚不清楚。
本研究旨在研究抗组胺药对体外抗原刺激后 CD14+细胞产生 TARC 和 MDC 的影响。
从花粉症患者中制备 CD14+细胞,用日本扁柏花粉特异性过敏原(Cry j 1)刺激,同时存在氮卓斯汀(AZE)、酮替芬(KET)、非索非那定(FEX)和奥沙米特(OXA),共培养 6 天。通过 ELISA 检测培养上清液中的 TARC 和 MDC 水平。我们还研究了 FEX 在 Cry j 1 刺激后对 CD14+细胞中 TARC 和 MDC mRNA 表达、丝裂原活化蛋白激酶(MAPKs)磷酸化和转录因子激活的影响。
250ng/ml 的 FEX(几乎等于治疗血药浓度)显著抑制 TARC 和 MDC 的产生。然而,AZE、OXA 和 KET 抑制这些因子产生所需的浓度高于其治疗血药浓度。250ng/ml 的 FEX 还抑制了 NF-κB 激活、p38 MAPK 和细胞外信号调节激酶 1 和 2 的磷酸化以及 TARC 和 MDC mRNA 的表达。
这些结果表明,抗组胺药,特别是 FEX,通过干扰抗原介导的信号转导抑制 CD14+细胞中 CC 趋化因子的产生,并导致过敏性疾病状态或情况的有利修饰。